Evidence map›Paper›PMID 41023731›Full record

ArticleCancer science2025

Design and Evaluation of Eb

Tomokazu Ohishi, Hiroyuki Suzuki, Mika K Kaneko, Tomohiro Tanaka, Akiko Harakawa, Junjiro Yoshida, Daisuke Tatsuda, Yukinari Kato, Manabu Kawada

Abstract read
In one paragraph

Article in Cancer science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Tomokazu OhishiInstitute of Microbial Chemistry (BIKAKEN), Laboratory of Oncology, Microbial Chemistry Research Foundation, Tokyo, Japan.ORCID https://orcid.org/0000-0002-9039-4474
Hiroyuki SuzukiDepartment of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.ORCID https://orcid.org/0000-0003-2646-5132
Mika K KanekoDepartment of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.
Tomohiro TanakaDepartment of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.
Akiko HarakawaInstitute of Microbial Chemistry (BIKAKEN), Numazu, Microbial Chemistry Research Foundation, Shizuoka, Japan.
Junjiro YoshidaInstitute of Microbial Chemistry (BIKAKEN), Laboratory of Oncology, Microbial Chemistry Research Foundation, Tokyo, Japan.
Daisuke TatsudaInstitute of Microbial Chemistry (BIKAKEN), Laboratory of Oncology, Microbial Chemistry Research Foundation, Tokyo, Japan.
Yukinari KatoDepartment of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.ORCID https://orcid.org/0000-0001-5385-8201
Manabu KawadaInstitute of Microbial Chemistry (BIKAKEN), Laboratory of Oncology, Microbial Chemistry Research Foundation, Tokyo, Japan.ORCID https://orcid.org/0000-0001-9348-4240

Funding

Japan Agency for Medical Research and Development JP24ck0106730Japan Agency for Medical Research and Development JP25am0521010Japan Agency for Medical Research and Development JP25ama121008Japan Agency for Medical Research and Development JP25ama221339Japan Agency for Medical Research and Development JP25bm1123027Japan Society for the Promotion of Science 22K06783Japan Society for the Promotion of Science 24K18268Japan Society for the Promotion of Science 25K10553
6 · The paper itself

Abstract

Breast cancer remains a leading cause of cancer mortality worldwide, underscoring the urgent need for novel and effective therapeutic strategies. Eph receptor tyrosine kinases, particularly EphB4, exhibit diverse roles in cancer biology, acting as either tumor promoters or suppressors depending on the cellular environment and ligand engagement. EphB4 is frequently overexpressed in breast cancer and contributes to dysregulated signaling and tumor progression through the abnormal interaction with its ligand Ephrin-B2. We herein developed an improved anti-EphB4 monoclonal antibody, Eb

Indexed as

Antibodies, MonoclonalBreast NeoplasmsReceptor, EphB4AnimalsAntibody-Dependent Cell CytotoxicityCell Line, TumorCell ProliferationCHO CellsCricetulusEphrin-B2FemaleHumansMCF-7 CellsMiceXenograft Model Antitumor AssaysAntibodies, MonoclonalEPHB4 protein, humanEphrin-B2Receptor, EphB4antibody‐dependent cellular cytotoxicity (ADCC)breast cancercomplement‐dependent cytotoxicity (CDC)EphB4ligand blockade

Identifiers

PMID41023731
PMCPMC12666464

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.